Keryx Biopharmaceuticals — Investor Presentation (September 2016)
27 slides from Keryx Biopharmaceuticals's investor presentation, Sep 7, 2016
Slide 1: Keryx Biopharmaceuticals, Inc.
Keryx Biopharmaceuticals, Inc. Keryx Biopharmaceuticals, Inc. September 7, 2016 Exhibit 99.1
Slide 2: Safe Harbor Statement
Safe Harbor Statement Various remarks that we make about our future expectations, plans and prospects constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Important factors may cause our actual results to differ
Slide 3: Building a Leading Renal Company
Building a Leading Renal Company Today Near Term Future One medicine, multiple indications Multi-product company focused on improving the lives of people with renal disease One medicine, one indication Auryxia is currently indicated for the control of serum phosphorus levels in CKD patients on dialy
Slide 4: Auryxia: A Market Leading Medicine for Two Complications of CKD
2016 2017 Future Potential Leverage expanded field team Increase utilization Increase breadth and depth of prescribing Generate further data to support differentiation Built brand awareness Refined sales messaging Introduced samples Established reimbursement Expanded field team Drive awareness of ID
Slide 5: Second Quarter 2016 Highlights
Source: IMS NPA, DaVita and Fresenius * Prior to supply interruption Prescription Volume Increased ~44% from 1Q 2016 to 2Q 2016 ~13,150 Auryxia prescriptions in 2Q 2016 45% of Auryxia prescriptions in 2Q 2016 not captured by IMS Volume growth driven by increased breadth and depth of prescribing Incr
Slide 6: Overview of Auryxia Supply Interruption
Production-related issue converting API to finished drug product Does not affect safety profile of currently available Auryxia Working with two contract manufacturers to restore supply CMO1 Identified step in process where issue is occurring Working together to resolve issue and resume production CM
Slide 7: How We View the CKD Market in the U.S.
How We View the CKD Market in the U.S. Sources: http://www.kidney.org/kidneydisease; U.S. Renal Data System, USRDS 2013 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive an
Slide 8: Multiple Complications Associated with CKD
Multiple Complications Associated with CKD Caused by changes in calcium and phosphate levels Occurs early and progresses as kidney function declines Treated with phosphate binders, vitamin D, calcimimetics Acidosis Hyperglycemia Hypertension Hyperlipidemia Salt and fluid retention Risk increases as
Slide 9: Progression of Chronic Kidney Disease
Progression of Chronic Kidney Disease Progressing patients typically referred to nephrologist Prepare for renal replacement therapy Patients initiate dialysis GFR (mL/min) Often not diagnosed Patients typically under care of PCP Moderate to severe loss of kidney function Severe loss of kidney functi
Slide 10: Auryxia (Ferric Citrate) Mechanism of Action
Auryxia® (Ferric Citrate) Mechanism of Action Phosphate Management Anemia Management 2 1 3 The ferric iron component binds to dietary phosphate in the GI tract and precipitates as ferric phosphate This compound is insoluble and excreted in the stool Ferric citrate has shown to increase serum iron pa
Slide 11: Today – Auryxia Controls Elevated Serum Phosphorus Levels in People on Dialysis
Today – Auryxia Controls Elevated Serum Phosphorus Levels in People on Dialysis
Slide 12: Patient Population for Current Auryxia Indication
Patient Population for Current Auryxia Indication Stage 1 Stage 2 Stage 3 Stage 4 GFR (mL/min) Auryxia is currently indicated for the control of serum phosphorus levels in chronic kidney disease patients on dialysis Stage 5D ~450,000 patients on dialysis 70-80% on phosphate binders
Slide 13: Current Auryxia (Ferric Citrate) Indication
Current Auryxia® (Ferric Citrate) Indication Phosphate Management Non-calcium, non-chewable, absorbable, iron-based phosphate binder Pharmacodynamic properties have shown to increase serum iron parameters, including TSAT and ferritin Established safety profile Most common AEs GI-related Recommended
Slide 14: Auryxia Patient Profiles
Auryxia Patient Profiles SWITCH PATIENTS Switched from Current Binder 30% - 40% of patients have phosphate levels above target range Reasons for switches: GI side effects, concern about calcium levels, lack of efficacy, pill burden Logical for Auryxia utilization NEW PATIENTS New to Dialysis Patient
Slide 15: Solid Fundamentals to Support Return to Market
Solid Fundamentals to Support Return to Market Physician Payer Patient 44% increased prescription volume over 1Q Increased breadth and depth of adoption Expanded field base team fully trained Sound commercial strategy Majority of phosphate binder patients have unrestricted access ~70% of co-pays <$1
Slide 16: Near Term: Potential to Treat Iron Deficiency Anemia in NDD-CKD
Near Term: Potential to Treat Iron Deficiency Anemia in People with NDD-Chronic Kidney Disease
Slide 17: Treating IDA in NDD-CKD Represents a Significant Expansion Opportunity
Treating IDA in Patients with NDD-CKD Represents a Significant Expansion Opportunity for Auryxia Sources: http://www.kidney.org/kidneydisease; U.S. Renal Data System, USRDS 2015 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States, National Institutes
Slide 18: Iron Deficiency Anemia Symptoms
Iron Deficiency Anemia Symptoms Headaches Extreme fatigue Loss of appetite Dizziness Impaired concentration Memory problems Reduced energy Reduced libido Disrupted sleep Muscle weakness Iron Deficiency Anemia
Slide 19: Need Exists for Effective, Well Tolerated, Convenient IDA Treatment
Oral Iron Widely available, inexpensive Generally viewed as ineffective due to: Tolerability, and Bioavailability/absorption Nephrologists report low satisfaction with existing oral iron therapies Viewed by most nephrologists as effective treatment Not routinely used in NDD-CKD patients with IDA due
Slide 20: Potential Ferric Citrate Label Expansion
Potential Ferric Citrate Label Expansion Stage 1 Stage 2 Stage 3 Stage 4 Stage 5/5D GFR (mL/min) Potential: Ferric Citrate indicated for treatment of iron deficiency anemia in adults with Stage 3-5 non-dialysis CKD Hemoglobin levels progressively fall Phosphorus levels progressively rise Future * Au
Slide 21: Baseline Laboratory Characteristics (ITT Population)
Baseline Laboratory Characteristics (ITT Population) Mean Baseline Laboratory Values Ferric Citrate (N=117) Placebo (N=115) Hemoglobin (g/dL) 10.4 10.4 TSAT (%) 20.2 19.6 Ferritin (ng/mL) 85.9 81.7 Serum phosphorus (mg/dL) 4.2 4.1 Keryx Biopharmaceuticals Announces Positive Top-line Results from Piv
Slide 22: IDA Phase 3 Top-line Results: Efficacy Endpoints
*Sustained treatment effect on Hgb was defined as a mean change from baseline ≥0.75 g/dL over any 4-week time period during the 16-week, randomized efficacy period, provided that an increase of at least 1.0 g/dL had occurred during that 4-week period. Randomized Efficacy Period (16 Weeks) Ferric Cit
Slide 23: IDA Phase 3 Top-line Results: Safety
AE Category Ferric Citrate (N=117) % (n) Placebo (N=116) % (n) Most common AEs Diarrhea 20.5 (24) 16.4 (19) Constipation 18.8 (22) 12.9 (15) Discolored feces 14.5 (17) 0 Nausea 11.1 (13) 2.6 (3) SAEs 12.0 (14) 11.2 (13) AEs leading to discontinuation 10.3 (12) 8.6 (10) Death 1.7 (2) 0 The majority o
Slide 24: Ferric Citrate Has Potential to Benefit Many More Patients
Ferric Citrate has Potential to Benefit Many More Patients with Chronic Kidney Disease Anemia Management Phase 3 study for IDA, NDD-CKD demonstrated statistically significant differences between the ferric citrate and placebo groups for the primary and all pre-specified secondary endpoints Expect to
Slide 25: Potential to Manage Two Complications of CKD
Potential to Manage Two Complications of CKD Phosphate Management Anemia Management Auryxia is currently indicated for the control of serum phosphorus levels in CKD patients on dialysis; Ferric citrate is being evaluated for use in non-dialysis dependent CKD patients as a treatment for iron deficien
Slide 26: Key Takeaways
Key Takeaways Expect to make Auryxia available to patients on dialysis during 4Q 2016 Submit sNDA for potential label expansion of Auryxia Present IDA/CKD phase 3 data to medical community Developing go-to-market strategy for IDA/NDD-CKD opportunity Auryxia is currently indicated for the control of
Slide 27: Keryx Biopharmaceuticals, Inc.
Keryx Biopharmaceuticals, Inc. Keryx Biopharmaceuticals, Inc. September 7, 2016
Keryx Biopharmaceuticals — Investor Presentation (September 2016) on 6ix